Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

NCT05671835 is registered in ClinicalTrials.gov with Tvardi Therapeutics, Incorporated as lead sponsor.

NCT NCT05671835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05671835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Lead sponsor
Tvardi Therapeutics, Incorporated
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2023
Completion date
August 14, 2025
Enrollment
100 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis